Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...
August 07, 2023 07:15 ET | Source: Passage Bio

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF...
August 07, 2023 07:00 ET | Source: Passage Bio

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...
August 01, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
July 31, 2023 07:00 ET | Source: Passage Bio

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
June 05, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system...
May 11, 2023 07:00 ET | Source: Passage Bio

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023Submitted protocol amendment to regulatory...
May 04, 2023 07:00 ET | Source: Passage Bio

Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award

PHILADELPHIA, May 04, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
April 21, 2023 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
April 17, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right